G
Gabriele Minuti
Researcher at Academy for Urban School Leadership
Publications - 47
Citations - 1927
Gabriele Minuti is an academic researcher from Academy for Urban School Leadership. The author has contributed to research in topics: Lung cancer & Internal medicine. The author has an hindex of 15, co-authored 35 publications receiving 1417 citations.
Papers
More filters
Journal ArticleDOI
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
Armida D'Incecco,M. Andreozzi,Vienna Ludovini,Elisa Rossi,Alessandra Capodanno,Lorenza Landi,Carmelo Tibaldi,Gabriele Minuti,Jessica Salvini,E. Coppi,Antonio Chella,Gabriella Fontanini,Maria Elena Filice,Luigi Tornillo,R. M. Incensati,S. Sani,L. Crinò,Luigi Terracciano,Federico Cappuzzo +18 more
TL;DR: PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies.
Journal ArticleDOI
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Marina Chiara Garassino,Jennifer G. Whisenant,Li-Ching Huang,Annalisa Trama,Valter Torri,Francesco Agustoni,Javier Baena,Giuseppe Luigi Banna,Rossana Berardi,Anna Cecilia Bettini,Emilio Bria,Matteo Brighenti,Jacques Cadranel,Alessandro De Toma,Claudio Chini,Alessio Cortellini,Enriqueta Felip,Giovanna Finocchiaro,Pilar Garrido,Carlo Genova,Raffaele Giusti,Vanesa Gregorc,Francesco Grossi,Federica Grosso,Salvatore Intagliata,Nicla La Verde,Stephen V. Liu,Julien Mazieres,Edoardo Mercadante,Olivier Michielin,Gabriele Minuti,Denis Moro-Sibilot,Giulia Pasello,Antonio Passaro,Vieri Scotti,Piergiorgio Solli,Elisa Stroppa,Marcello Tiseo,Giuseppe Viscardi,Luca Voltolini,Yi-Long Wu,Silvia Zai,Vera Pancaldi,Anne Marie C. Dingemans,Jan P. van Meerbeeck,Fabrice Barlesi,Heather A. Wakelee,Solange Peters,Leora Horn +48 more
TL;DR: With an ongoing global pandemic of COVID-19, the data suggest high mortality and low admission to intensive care in patients with thoracic cancer and whether mortality could be reduced with treatment in intensive care remains to be determined.
Journal ArticleDOI
Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.
Lorenza Landi,Rita Chiari,Marcello Tiseo,F. D'Incà,Claudio Dazzi,Antonio Chella,Angelo Delmonte,Laura Bonanno,Diana Giannarelli,Diego Cortinovis,Filippo de Marinis,Gloria Borra,Alessandro Morabito,Cesare Gridelli,Domenico Galetta,Fausto Barbieri,Francesco Grossi,Enrica Capelletto,Gabriele Minuti,Francesca Mazzoni,Claudio Verusio,Emilio Bria,Greta Alì,Rossella Bruno,Agnese Proietti,Gabriella Fontanini,Lucio Crinò,Federico Cappuzzo +27 more
TL;DR: Crizotinib induces response in a fraction of MET-deregulated NSCLC, and no difference in any clinical endpoint was observed between MET-amplified and exon 14–mutated patients.
Journal ArticleDOI
Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer.
Gabriele Minuti,Federico Cappuzzo,R. Duchnowska,Jacek Jassem,Alessandra Fabi,Terence J. O'Brien,Adelita D. Mendoza,Lorenza Landi,Wojciech Biernat,Bogumiła Czartoryska-Arłukowicz,T Jankowski,Dorota Zuziak,J Zok,Barbara Szostakiewicz,Małgorzata Foszczyńska-Kłoda,A Tempinska-Szalach,Elisa Rossi,Marileila Varella-Garcia +17 more
TL;DR: High GCNs of MET and HGF associate with an increased risk of trastuzumab-based therapy failure in HER2-positive MBC.
Journal ArticleDOI
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
Lorenza Landi,F. D'Incà,Alain Gelibter,Rita Chiari,Francesco Grossi,Angelo Delmonte,Antonio Passaro,Diego Signorelli,Francesco Gelsomino,Domenico Galetta,Diana Giannarelli,Hector Soto Parra,Gabriele Minuti,Marcello Tiseo,Maria Rita Migliorino,Francesco Cognetti,Luca Toschi,Paolo Bidoli,Francovito Piantedosi,Luana Calabrò,Federico Cappuzzo +20 more
TL;DR: Bone metastases impairs immunotherapy efficacy and accurate bone staging should be included in clinical trials with immunotherapy.